Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Leukemia |
Free Subscription
1 Acta Haematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic
Leukemia patient with Richter Transformation: A Case Report and Review of the
Literature.
Acta Haematol. 2024 Feb 24. doi: 10.1159/000537791.
PubMed
Abstract available
Pituitary apoplexy in acute promyelocytic leukemia.
Am J Hematol. 2024 Feb 29. doi: 10.1002/ajh.27277.
PubMed
Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic
leukemia.
Am J Hematol. 2024 Feb 27. doi: 10.1002/ajh.27272.
PubMed
Abstract available
Neutrophilic leukemoid reaction or chronic neutrophilic leukemia-not always so
simple.
Am J Hematol. 2024 Feb 23. doi: 10.1002/ajh.27268.
PubMed
Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
Ann Hematol. 2024 Mar 1. doi: 10.1007/s00277-024-05673.
PubMed
Low incidence of tumor lysis syndrome in elderly patients with chronic
lymphocytic leukemia treated with venetoclax under real-world conditions: results
from the prospective observational VeRVe study.
Ann Hematol. 2024 Feb 29. doi: 10.1007/s00277-024-05638.
PubMed
Abstract available
Myelodysplasia-related gene mutations are associated with favorable prognosis in
patients with TP53-mutant acute myeloid leukemia.
Ann Hematol. 2024 Feb 27. doi: 10.1007/s00277-024-05679.
PubMed
Abstract available
CD38-directed, single-chain T cell-engager targets leukemia stem cells through
IFNgamma-induced CD38 expression.
Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
PubMed
Abstract available
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The
role of kinase type and SH3 domain.
Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
PubMed
Abstract available
A new SAGA for AML: targeting SGF29 in AML.
Blood. 2024;143:657-658.
PubMed
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly
diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein
phenotype.
Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656.
PubMed
Abstract available
Mutant U2AF1-induced mis-splicing of mRNA translation genes confers resistance to
chemotherapy in acute myeloid leukemia.
Cancer Res. 2024 Feb 28. doi: 10.1158/0008-5472.CAN-23-2543.
PubMed
Abstract available
First report of familial mixed phenotype acute leukemia: shared clinical
characteristics, Philadelphia translocation, and germline variants.
Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03724.
PubMed
Abstract available
Predictive factors for L-asparaginase hypersensitivity in pediatric acute
lymphoblastic leukemia.
Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03725.
PubMed
Abstract available
Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal
Period: Case Report and Literature Review.
J Pediatr Hematol Oncol. 2024;46:e176-e179.
PubMed
Abstract available
Coronavirus Disease 2019 mRNA Vaccination Appears Safe in Pediatric Patients With
Hypersensitivity to Polyethylene Glycolated Escherichia coli L-asparaginase.
J Pediatr Hematol Oncol. 2024;46:e202-e204.
PubMed
Abstract available
Hypoglycemia Associated With PEG-asparaginase and 6-MP Therapy During Treatment
of Acute Lymphoblastic Leukemia in Pediatric Patients: A Case Series.
J Pediatr Hematol Oncol. 2024;46:e121-e126.
PubMed
Abstract available
TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the
eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
PubMed
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and
tolerability of pelabresib in patients with myeloid malignancies.
Leuk Lymphoma. 2024;65:503-510.
PubMed
Abstract available
Identifying CLL patients at high risk of atrial fibrillation on treatment using
machine learning.
Leuk Lymphoma. 2024;65:449-459.
PubMed
Abstract available
Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL:
are we there yet?
Leuk Lymphoma. 2024;65:440-448.
PubMed
Abstract available
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes /
germline predisposition syndromes: Back under the microscope.
Leuk Res. 2024;137:107441.
PubMed
Abstract available
When the devil is in the details: Similarities and differences between WHO and
ICC classifications of AML.
Leuk Res. 2024;137:107440.
PubMed
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for
chronic myeloid leukemia: managing intolerance and resistance.
Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187.
PubMed
Abstract available
circFAM193B interaction with PRMT6 regulates AML leukemia stem cells
chemoresistance through altering the oxidative metabolism and lipid peroxidation.
Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189.
PubMed
Abstract available
Correction: Treatment-free remission after a second TKI discontinuation attempt
in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim
results from the DAstop2 trial.
Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184.
PubMed
Influence of co-mutational patterns in disease phenotype and clinical outcomes of
chronic myelomonocytic leukemia.
Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190.
PubMed
Germline variants in patients developing second malignant neoplasms after therapy
for pediatric acute lymphoblastic leukemia-a case-control study.
Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173.
PubMed
Aging and comprehensive molecular profiling in acute myeloid leukemia.
Proc Natl Acad Sci U S A. 2024;121:e2319366121.
PubMed
Abstract available
Enhancing chimeric antigen receptor T cell therapy by modulating the p53
signaling network with Delta133p53alpha.
Proc Natl Acad Sci U S A. 2024;121:e2317735121.
PubMed
Abstract available
Thank you for your interest in scientific medicine.